Methods: In vitro antidiabetic activity was investigated using α-glucosidase inhibition assay with acarbose (62.5, 125, 500 and 1000 µg/ml) 1000 (74.78 ± 0.92), 500 (65.11 ± 0.07), 250 (57.55 ± 0.41), 125 (51.55 ± 0.67) and 62.5 ( 44.00 ± 0.57 
INTRODUCTION
Diabetes is one of the leading causes of death worldwide and according to World Health Organization (WHO), diabetes will be the 7 th leading cause of death by 2030 [1] . It is a metabolic disease with major clinical manifestation of chronic hyperglycemia. The most prominent pathway in the management of diabetes is to reduce the postprandial hyperglycemia by reducing the absorption of glucose from the intestinal tract [2] . This reduction in glucose absorption is possible by inhibiting a key enzyme responsible for the process, i.e. α-glucosidase. The inhibitors of α-glucosidase will reduce the breakdown of complex carbohydrates to simple sugar units. The reduction in breakdown of complex carbohydrate will lead to the reduction in postprandial glucose level [3] .
Conyza canadensis (L.) Cronquist (Asteraceae) is an annual herb, commonly known as Canadian horseweed, Canadian fleabane or Plaeet by the locals [4] . It is used in traditional medicine for the treatment of diarrhea, dysentery, wound healing, muscular pain, arthritis, cystitis, bronchitis and as a diuretic agent [5, 6] . Conyza canadensis is reported to possess anti-inflammatory, antioxidant, antibacterial, antiplatelet, cytotoxic [7] , antiviral [8] and antimelanoma [9] activities.
The major constituent isolated from the aerial parts of Conyza canadensis is limonene [6] , other constituents isolated and reported include 2Z, 8Z-matricaria ester, (R)-(+)-limonene, trans-α-bergamotene, erigeronol 1 (3-O-(hydroxyacetyl)-23,28-dihydroxy-β-amyrin) [9] , conyzapyranone A and B, 4 Z,8 Z-matricaria-γ-lactone, 4 E,8 Z-matricaria-γ-lactone, 9,12,13-trihydroxy 10(E) octadecenoic acid, epifriedelanol, friedeline, taraxerol, simiarenol, spinasterol and apigenin [10] . 3-β-erythrodiol was also isolated and found to be effective in inhibiting MKN-45 human gastric cells in mouse xenograft model [11] . The phytochemicals present in plants are responsible for their pharmacological activities. Various important phytocomponents present in Conyza canadensis have been previously reported as possessing antidiabetic activity in various animal models. D-Limonene, β-sitosterol and a sphingolipid have shown strong antidiabetic properties in streptozotocin-induced diabetic rats [12, 13] .
The present study is designed to investigate the effect of Conyza canadensis on the blood glucose level and oral glucose tolerence in alloxan induced diabetes in mice.
EXPERIMENTAL Plant material and extraction
The whole plant of Conyza canadensis was collected from Islamabad, Pakistan in July 2015 and authenticated by Dr. Mushtaq Ahmad, a taxonomist at Department of Plant Sciences, Quaid-e-Azam University, Islamabad, Pakistan. Plant specimen was deposited at the Department herbarium (voucher no. 804).
The plant material was shade dried at room temperature and then grounded to a coarse powder. The powdered material was macerated in 70 % methanol for 10 days with regular shaking at intervals. The crude methanol extract was obtained by concentrating on rotary evaporator under reduced pressure at 40 -50 ° C [14] .
Chemicals
The details of chemicals used in the α-glucosidase inhibitory assay are; glucopyranoside (Sigma, product code 101547038), α-glucosidase (Sigma, product code 1001962968), acarbose (Alfa Aesar, CAS 56180-94-0) and sodium carbonate (Merck). Alloxan monohydrate was purchased from Sigma-Aldrich Co. LLC, USA and Metformin HCl from Caraway Pharmaceuticals, Islamabad, Pakistan. All the chemicals used were of analytical grade.
Animals
Balb-C mice (25 - 
Preliminary phytochemical screening
Preliminary phytochemical testing was performed for the detection of alkaloids, tannins, triterpenes, proteins, carbohydrates, flavonoids, saponins and steroids, using standard procedures [16] . Alkaloids were tested using Mayer's reagent and Dragendroff's reagent. Tannins were considered to be positive when addition of lead acetate to the test material of Cc.Cr gave cream yellow color. Triterpenes were detected positive when addition of sulphuric acid produced a red colouration using Liebermann Burchard test.
Proteins were tested with ninhydrin, appearance of blue colour confirmed the presence of proteins. Benedict's test was used to detect carbohydrates, orange red precipitates were considered positive indication. If plant material treated with chloroform and sulfuric acid produced red colour, confirmed steroids presence [17] . Saponins were tested using Froth's test [18] .
In-vitro α-glucosidase inhibition assay
The α-glucosidase inhibitory assay for Cc.Cr was performed according to standard procedure [19] . The enzyme solution was prepared by dissolving 0.5 unit / mL of α-glucosidase in 0.1M phosphate buffer (pH 6.9). The enzyme solution contains 20 µL of α-glucosidase (0.5 unit / ml) and 120 µl of 0.1 M phosphate buffer. Substrate solution of pnitrophenyl-α-D-glucopyranoside (5 mM) was made in the buffer solution. Test samples were prepared in a concentration range of 62.5-1000 µg/ml, this was then mixed with the enzyme solution and incubated for 15 min at 37 o C. Finally, substrate solution (20 µl) was added to the mixture and this was incubated for another 15 min at 37 o C.
The reaction was completed by the addition of 80 µL of 0.2M sodium carbonate solution. The absorbance were measured at 405 nm using UVspectrophotometer (Thermo Electron Corporation, USA). The system without α-glucosidase was used as blank and acarbose was used as positive control. The experiments were performed in triplicate and inhibitory activity (H) calculated as in Eq 1.
H (%) = {(Ac -As)/Ac}100 …………….. (1) where Ac and As are the absorbance of control and test samples, respectively.
Acute toxicity studies
The acute oral toxicity test was performed as reported by [19] . The mice (n = 6) in each group were fasted overnight and administered Cc.Cr orally at doses of 1, 3 and 5 g/kg. Animals were then kept under observation for 48 h and observed for any signs of diarrhea, discomfort, pain, behavioral, neurological changes, convulsions, coma or death.
Induction of diabetes, blood glucose level and body weight measurement
Animals were fasted for 12 h. The solution of alloxan (200 mg/kg) in 0.2 mL saline was injected intra-peritoneally for the induction of diabetes [20] . After 48 h, fasting glucose levels of test animals were obtained. Animals with blood glucose levels above 200 mg/dl along with signs of polyuria and polydipsia were considered diabetic and included in the study. The test animals were divided into 7 groups (n = 5). Group I (non-diabetic normal control, given saline), Group II (diabetic control treated with alloxan 200 mg/kg), Group III, IV, V and VI include alloxan treated diabetic animals which received 10, 30, 100 and 300 mg/kg doses of the methanolic extract respectively. The Group VII was diabetic animals, treated with metformin (500 mg/kg), as reference drug. Each group was administered the respective test drug daily for 15 consecutive days with monitoring of blood glucose levels, using EASYGLUCO Auto-coding Glucometer and body weight (g) at regular intervals.
Oral glucose tolerance test
The mice were fasted overnight (14-15 h) and divided into non-diabetic control group (treated with saline 0.2 mL), diabetic control group (administered alloxan 200 mg/kg for induction of diabetes), test group (treated with Cc.Cr 300 mg/kg) and standard drug (treated with metformin 500 mg/kg) group, 30 min prior to oral D-glucose (2 g/kg) challenge. Blood for glucose determination was measured by tail-prick method at different time points: 0 min (before glucose load), then at 30, 60, 90 and 120 min after glucose administration [21] .
Statistical analysis
Data was expressed as mean ± standard error of mean (SEM) and were analyzed by one-way analysis of variance (ANOVA) followed by Tukey post-hoc test. P < 0.05 was taken as significantly different [22] . The plots were analyzed using the GraphPad software (GraphPad, San Diego, CA, USA).
RESULTS

Phytochemical profile
The methanol extract of Conyza canadensis showed positive results for alkaloids, tannins, triterpenes, proteins, carbohydrates, saponins, flavonoids and steroids.
α-Glucosidase inhibition
The α-glucosidase inhibition of the Cc.Cr was performed at different concentrations and compared with the standard drug acarbose at the same tested concentration (Table 1) . Cc.Cr exhibited overwhelming enzyme inhibitory potential at various concentrations. At highest tested concentration (1000 µg/ml), Cc.Cr demonstrate 74.78 ± 0.92 % inhibition which was almost similar to that of the positive control at the same concentration (76.87 ± 0.06 % at 1000 µg/ml). Similarly, the observed inhibitions for Cc.Cr at concentrations of 500, 250, 125 and 62.5 µg/ml were 65.11 ± 0.07, 57.55 ± 0.41, 51.55 ± 0.67 and 44.00 ± 0.57 % respectively. The observed IC 50 s for the Cc.Cr and acarbose were 107 and 23 µg/ml respectively. 
Acute toxicity
The crude extract of Conyza canadensis did neither caused any mortality nor any signs of toxicity at the tested doses of 3 and 5 g/kg (n = 5).
Effect of Cc.Cr on blood glucose levels
The methanolic extract at doses of 10, 30, 100 and 300 mg/kg reduced the blood glucose of alloxan-induced diabetic mice (Figure 1 ), like that caused by metformin. The animals of nondiabetic control group at days 1, 5, 10 and 15 were having blood glucose levels of 110.0 ± 4.50, 113.0 ± 3.178, 115.4 ± 6.577 and 109.4 ± 4.106 mg/dl respectively. Blood glucose levels of alloxan (200 mg/kg) treated diabetic control group at days 1, 5, 10 and 15 were 256.2 ± 13.6, 259.0 ± 7.9, 269.8 ± 14.7 and 278. 4 
Effect of Cc.Cr on body weight
The methanolic extract at 30, 100 and 300 mg/kg doses increased body weight of the treated animals as shown in 
Effect of Cc.Cr on glucose tolerance
Figure 2: Blood glucose levels of oral glucose loaded mice of non-diabetic control group diabetic control group , Conyza canadensis and metformin pre-treated groups. Data are expressed as mean ± SEM (n = 5); *** P < 0. 001 compared to alloxan-induced diabetic control group
The crude extract (300 mg/kg) significantly (p < 0.001 vs diabetic control group) improved the tolerance of orally administered glucose, even better than that caused by metformin (500 mg/kg). After the glucose (2 g / kg) overload, blood glucose levels of non-diabetic normal control group at 0, 30, 60, 90 and 120 min were recorded as 91.9 ± 5.6, 179.3 ± 4.9, 160.2 ± 3.6, 137.4 ± 4.4 and 125.6 ± 3.2 mg/dl respectively. In the alloxan (200 mg/kg) treatment diabetic control group, blood glucose levels at 0, 30, 60, 90 and 120 min increased to 206.2 ± 2.9, 311.6 ± 20.2, 384.0 ± 24.4, 378.0 ± 23.05 and 336.8 ± 21.5 mg/dl, respectively. The blood glucose level of Cc.Cr (300 mg/kg) pretreated animals after glucose load (2 g/kg) at 0, 30, 60, 90 and 120 min were 93.40 ± 10.3, 135.2 ± 11.5, 122.0 ± 3.2, 87.80 ± 11.0 and 72.40 ± 4.9 mg/dl (p < 0.001 vs diabetic control group) respectively. The blood glucose levels of metformin (500 mg/kg) pretreated mice at 0, 30, 60, 90 and 120 min were 99.60 ± 6.1, 162 ± 4.8, 139.6 ± 2.1, 124.8 ± 2.6 and 114.6 ± 4.9 mg/dl (p < 0.001 vs diabetic control group) respectively (Figure 2 ).
DISCUSSION
Several agents have been used to induce diabetes in experimental animals, including alloxan.
Alloxan, a pyrimidine derivative (chemically as 2,4,5,6 tetraoxypyrimidine; 2, 4, 5, 6-pyrimidinetetrone), gets transported into the beta cells through GLUT2 transporter where it induces diabetes by selectively inhibiting glucokinase and causing beta cells necrosis by formation of reactive oxygen species [23] .
All animals treated with 200 mg/kg of alloxan showed marked increase in blood glucose levels up to 200 mg/dl and above after 72 h. The selected test animals were then treated with test drugs for 15 consecutive days. Conyza canadensis in a dose-dependent (10-300 mg/kg) and time-dependent (days 5-15 th ) fashion reduced blood glucose level in diabetic animals, similar to the effect of metformin, the standard antidiabetic drug. Metformin, acts by several pathways including impairing intestinal glucose absorption, enhancing insulin release from beta cells, inhibiting hepatic glucose production and increasing the uptake of glucose into the cells [24] . Weight loss is one of the complications of diabetes that occurs due to enhanced lipolysis. Reduction in body weight of diabetics is attributed to inadequacy of insulin and its function in fat metabolism [25] . Prevention of weight reduction in animals, treated with Cc.Cr indicates that Conyza canadensis has beneficial outcomes in preventing subsequent complication of weight loss, associated with hyperglycemia. In the glucose-loaded hyperglycemia model, employed to evaluate oral glucose tolerance, Cc.Cr displayed significantly better tolerance of glucose overload at different time intervals (30-120 min), similar to metformin. The excessive amount of glucose in blood impels insulin secretion. This secreted insulin stimulates peripheral glucose utilization and controls processing of glucose through several mechanisms [26] .
This property of Conyza canadensis in reducing blood glucose levels and simultaneously improving glucose tolerance, suggests its use as antidiabetic.
However, further advanced molecular studies will be needed to elucidate the underlying pharmacodynamics involved.
The observed antihyperglycemic effect of the plant can be attributed to its diverse phytoconstituent profile. Limonene isolated from aerial parts of Conyza canadensis is reported to be effective as an antidiabetic agent by inhibiting protein glycation up to 85.61% and also effectively reduced the blood glucose levels in the in-vivo experiments [27] . Other compounds of the plant; β-sitosterol and stigmasterol are also known to possess antidiabetic and antioxidant potentials [28, 29] .
CONCLUSION
The study reveals that Conyza canadensis exhibits α-glucosidase inhibition and antihyperglycemic action in alloxan-induced diabetic mice and improves tolerance of oral glucose overload. This study thus provides scientific evidence for the use of Conyza canadensis in the treatment of diabetes mellitus in traditional medicine. Future studies will be carried out to identify the active principle(s) of the plant that are responsible for its antidiabetic effect.
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